Enovis has launched the one-tray AltiVate Reverse Glenoid System, featuring modular, augmented baseplates, to expand its AltiVate Reverse glenoid implant offering.
The company designed the system, based on its central screw fixation design, which received the US Food and Drug Administration (FDA) 510(k) approval in May 2024.
It features a modular baseplate that provides neutral and 15° wedge options, along with several central compression screw lengths and diameters.
The baseplate boss was designed to preserve the glenoid vault by minimising bone removal compared to other similar designs.
In addition, the system introduces four new glenospheres to enhance its existing reverse shoulder prosthesis (RSP) range.
The new glenospheres allow surgeons to select from a wide array to meet each patient’s biomechanical requirements and enhance implant durability, said the company.
Enovis reconstructive business group president Louie Vogt said: “We are very pleased to offer a modular, augmented baseplate based on the proven central screw fixation principle of our legacy Reverse Shoulder Prosthesis (RSP) system.
“This addition to our market-leading AltiVate Reverse continues our long history of surgeon-driven innovation and commitment to exceptional patient outcomes.”
The US health regulator approved the system for use in reverse shoulder arthroplasty, including revisions, in which the position of the ball and socket are switched.
According to the company, reverse shoulder arthroplasty accounts for over 60% of the more than 200,000 shoulder replacements performed annually in the US.
Originally developed in the 1980s in Europe and FDA-approved in 2003, indications for this procedure continue to expand, increasing the demand for implants.
According to Enovis, Dr Mark Frankle conducted the inaugural surgery using the AltiVate Reverse Glenoid at Tampa General Hospital in Tampa, Florida.
Frankle said: “The new AltiVate Reverse Glenoid is a major innovation for my practice.
“I now have one system with a variety of options to treat most, if not all, of my patients. It is simple and efficient while still offering the fixation and implant options I need, and it’s very exciting to be the first to use it clinically.”
